ES2131069T3 - Expresion de proteinas recombinantes en bacterias atenuadas. - Google Patents

Expresion de proteinas recombinantes en bacterias atenuadas.

Info

Publication number
ES2131069T3
ES2131069T3 ES92905914T ES92905914T ES2131069T3 ES 2131069 T3 ES2131069 T3 ES 2131069T3 ES 92905914 T ES92905914 T ES 92905914T ES 92905914 T ES92905914 T ES 92905914T ES 2131069 T3 ES2131069 T3 ES 2131069T3
Authority
ES
Spain
Prior art keywords
expression
attenuated bacteria
recombinant proteins
promoter
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905914T
Other languages
English (en)
Inventor
Ian George Charles
Steven Neville Chatfield
Neil Fraser Fairweather
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919104596A external-priority patent/GB9104596D0/en
Priority claimed from GB919121208A external-priority patent/GB9121208D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2131069T3 publication Critical patent/ES2131069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

UNA BACTERIA ATENUADA LA CUAL ES CAPAZ DE EXPRESAR UNA PROTEINA HETEROLOGA, SIENDO BAJO EL CONTROL DE UN PROMOTOR CUYA ACTIVIDAD ES INDUCIDA POR CONDICIONES ANAEROBICAS, SE PUEDE USAR COMO UNA VACUNA. UN PROMOTOR ADECUADO ES EL PROMOTOR "NIRB".
ES92905914T 1991-03-05 1992-03-05 Expresion de proteinas recombinantes en bacterias atenuadas. Expired - Lifetime ES2131069T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919104596A GB9104596D0 (en) 1991-03-05 1991-03-05 Production of recombinant proteins
GB919121208A GB9121208D0 (en) 1991-10-04 1991-10-04 Vaccines

Publications (1)

Publication Number Publication Date
ES2131069T3 true ES2131069T3 (es) 1999-07-16

Family

ID=26298523

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905914T Expired - Lifetime ES2131069T3 (es) 1991-03-05 1992-03-05 Expresion de proteinas recombinantes en bacterias atenuadas.

Country Status (18)

Country Link
US (2) US5547664A (es)
EP (1) EP0574466B1 (es)
JP (1) JP3415145B2 (es)
KR (1) KR100240182B1 (es)
AT (1) ATE180280T1 (es)
AU (1) AU664360B2 (es)
CA (1) CA2099841C (es)
CZ (1) CZ285118B6 (es)
DE (1) DE69229221T2 (es)
DK (1) DK0574466T3 (es)
ES (1) ES2131069T3 (es)
FI (1) FI110008B (es)
GR (1) GR3030778T3 (es)
HU (1) HU219535B (es)
NO (1) NO309331B1 (es)
PL (1) PL170938B1 (es)
SK (1) SK55593A3 (es)
WO (1) WO1992015689A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
DK0652962T3 (da) * 1992-07-31 1999-08-23 Medeva Holdings Bv Ekspression af rekombinante fusionsproteiner i attenuerede bakterier
JPH09500540A (ja) * 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー．ヴイ． ワクチン組成物
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP1012232B1 (en) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
FR2778922A1 (fr) * 1998-05-19 1999-11-26 Pasteur Institut Polynucleotides contenant des sequences de regulation de la synthese de toxines de clostridium, et microorganismes les comprenant
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
AU780887B2 (en) 1999-04-09 2005-04-21 Zoetis Services Llc Anti-bacterial vaccine compositions
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
GB0024203D0 (en) * 2000-10-03 2000-11-15 Peptide Therapeutics Ltd Stabilisation of plasmid inheritance in bacteria
WO2002038739A1 (en) * 2000-11-09 2002-05-16 Univ Queensland Bacterial expression systems
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
AUPR977601A0 (en) * 2001-12-28 2002-01-31 Delta Biotechnology Limited Defective entities and uses therefor
GB0205376D0 (en) * 2002-03-07 2002-04-24 Royal Holloway University Of L Spore germination
WO2004001020A2 (en) * 2002-06-19 2003-12-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Methods and means to promote gut absorption
EP1560935A2 (en) * 2002-11-15 2005-08-10 VIB vzw Self-containing lactobacillus strain
CA2576280A1 (en) 2004-08-13 2006-02-16 Barry J. Marshall Helicobacter pylori-based delivery system
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
RU2420569C2 (ru) 2005-11-29 2011-06-10 Актогеникс Нв Индукция толерантности к антигенам через слизистую
KR101460551B1 (ko) 2006-09-18 2014-11-18 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역 반응을 향상시키는 조성물 및 방법
ES2666658T3 (es) 2007-01-25 2018-05-07 Intrexon Actobiotics Nv Tratamiento de enfermedad inmune mediante suministro a la mucosa de antígenos
AU2008318615A1 (en) * 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
CA2704422C (en) 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
CN102477440A (zh) * 2010-11-29 2012-05-30 南京大学 治疗基因在厌氧组织靶向递送和选择性稳定表达方法及应用
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
ES2861576T3 (es) 2011-03-21 2021-10-06 Altimmune Inc Agente terapéutico inmunológico de acción rápida y prolongada
EA030929B1 (ru) 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
HK1219045A1 (zh) 2013-03-15 2017-03-24 The Board Of Trustees Of The University Of Arkansas 增强对肠道病原体免疫应答的组合物和方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
DE3735381A1 (de) * 1987-03-31 1989-05-03 Boehringer Mannheim Gmbh Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen
GB8730037D0 (en) * 1987-12-23 1988-02-03 Wellcome Found Vaccines
JPH0284172A (ja) * 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
DE3926076A1 (de) * 1989-04-21 1990-10-25 Boehringer Mannheim Gmbh Rekombinante dna und expressionsvektor
GB8912330D0 (en) * 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
GB9104596D0 (en) * 1991-03-05 1991-04-17 Wellcome Found Production of recombinant proteins

Also Published As

Publication number Publication date
NO932423L (no) 1993-07-02
AU664360B2 (en) 1995-11-16
PL170938B1 (pl) 1997-02-28
FI933757A0 (fi) 1993-08-26
NO932423D0 (no) 1993-07-02
JPH06505158A (ja) 1994-06-16
SK55593A3 (en) 1993-10-06
FI933757L (fi) 1993-08-26
CZ285118B6 (cs) 1999-05-12
PL296702A1 (en) 1993-07-26
JP3415145B2 (ja) 2003-06-09
DE69229221D1 (de) 1999-06-24
WO1992015689A1 (en) 1992-09-17
EP0574466A1 (en) 1993-12-22
DE69229221T2 (de) 1999-09-23
AU1350892A (en) 1992-10-06
US5547664A (en) 1996-08-20
GR3030778T3 (en) 1999-11-30
EP0574466B1 (en) 1999-05-19
US5683700A (en) 1997-11-04
CA2099841C (en) 2003-02-25
DK0574466T3 (da) 1999-11-08
HUT66833A (en) 1995-01-30
CZ100593A3 (en) 1994-01-19
KR100240182B1 (ko) 2000-01-15
NO309331B1 (no) 2001-01-15
HU219535B (hu) 2001-05-28
HU9302492D0 (en) 1993-11-29
CA2099841A1 (en) 1992-09-06
FI110008B (fi) 2002-11-15
ATE180280T1 (de) 1999-06-15

Similar Documents

Publication Publication Date Title
ES2131069T3 (es) Expresion de proteinas recombinantes en bacterias atenuadas.
ES2059547T3 (es) Expresion y secrecion mejoradas de proteinas heterologas en levadura, empleando secuencia conductora de factor alfa truncado.
ES8801851A1 (es) Un metodo para producir bacterianamente un polipeptido heteralogo que tiene actividad somatotropinica.
ES8507176A1 (es) Un metodo de sintetizar un polipeptido seleccionado
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
LU91304I2 (fr) A tryn-antithrombin alfa
DE3586092D1 (de) Expression und sekretion von polypeptiden in eukaryoten unter kontrolle eines adenoviruspromotors.
ATE253119T1 (de) Verwendung des glucoamylasepromotors aus apergillus
DE3688418D1 (de) Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
FI100056B (fi) Ihmisproapolipoproteiinin A-I ilmaiseminen
ES2163864T3 (es) Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas.
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
ES2055686T3 (es) Procedimiento para preparar proteinas con factor de granulocitos-macrofagos "estimulador de colonias".
ES2179039T3 (es) Promotores especificos para el tapete de especies de brassicaceae.
ES2072900T3 (es) Expresion elevada de proteinas en levadura.
ES2150916T3 (es) Utilizacion del acido gentisico o del alcohol gentisilico para estabilizar peptidos y proteinas radiomarcados.
ES2074280T3 (es) Metodo para modificar el tropismo de celula, tejido o huesped de un microorganismo, microorganismos recombinantes obtenidos de este modo y su uso en medicina y medicina veterinaria.
ES8606490A1 (es) Un derivado de polipeptido de interferon-a humano
ES2043610T3 (es) Procedimiento para la produccion de un polipeptido hibrido del tipo activador de plasminogeno.
FI883005A7 (fi) Promoottoreita vieras-DNA:n ilmaisemiseksi metylotrofisissa bakteereissa, niiden talteenotto ja niiden käyttö.
ES2089122T3 (es) Vectores de expresion de adn recombinante y compuestos de adn que codifican la actividad de la isopenicilina n epimerasa.
EP0206200A3 (en) Human cholinesterase-type proteins and their production
DK62985A (da) Polypeptid
ES2062006T3 (es) Un psti humano modificado.
ATE120491T1 (de) Ausgeglichenes, konstitutives, induzierbares transkriptionssystem.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 574466

Country of ref document: ES